Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.30 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22388221 | 1.00 | HDAC6 (0.33) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL18419554 | 0.87 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL18658421 | 0.87 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL12776500 | 0.86 | CA14 (0.38) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL20568842 | 0.86 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL13452140 | 0.86 | CA14 (0.38) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL24500586 | 0.84 | CA1 (0.37) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL19472431 | 0.84 | HDAC6 (0.33) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL25124097 | 0.84 | HDAC6 (0.33) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL20225470 | 0.84 | HDAC6 (0.33) | HDAC6HDAC1HDAC2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-11236072-B2 | N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-02-01 | — | — | US | disclosed |
| EP-3661928-B1 | N-[(PYRIMIDINYLAMINO)PROPANYL]-, N-[(PYRIDYLAMINO)PROPANYL]- AND N-[(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2021-06-16 | — | — | EP | disclosed |
| EP-3442966-B1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]- AND N-[(PYRIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2020-10-14 | — | — | EP | disclosed |
| US-20200231575-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-,N-[PYRIDYLAMINO)PROPANYL]- AND N-[(PYRAZINYLAMINOL)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-07-23 | — | — | US | disclosed |
| US-10710984-B2 | N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-07-14 | — | — | US | disclosed |
| EP-3442964-B1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2020-05-06 | — | — | EP | disclosed |
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2019-04-18 | — | — | US | disclosed |
| US-20190112297-A1 | Novel N-[(Pyrimidinylamino)Propanyl]-and N-[(Pyridinylamino)Propanyl]Arylcarboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| WO-2019025275-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-, N-[(PYRIDYLAMINO)PROPANYL] - AND N-[(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-02-07 | — | — | WO | disclosed |
| US-9884854-B2 | N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9884854-B2 | N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2017178343-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N-[(PYRIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
| US-20170298053-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GHBH (DE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298053-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GHBH (DE) | 2017-10-19 | — | — | US | disclosed |
| WO-2017178341-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2012041227-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112297-A1 | Novel N-[(Pyrimidinylamino)Propanyl]-and N-[(Pyridinylamino)Propanyl]Arylcarboxamides | HCRTR1, HCRTR2, CNR1 | HDAC6 777/4885HDAC1 455/4885HDAC2 411/4885 |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | KRAS, NRAS, HRAS | HDAC6 1056/4885HDAC1 952/4885HDAC2 2164/4885 |
| US-10710984-B2 | N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides | HCRTR1, HCRTR2, CNR1 | HDAC6 894/4885HDAC1 489/4885HDAC2 432/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | HDAC6 954/4885HDAC1 1019/4885HDAC2 1755/4885 |
| US-20200231575-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-,N-[PYRIDYLAMINO)PROPANYL]- AND N-[(PYRAZINYLAMINOL)PROPANYL]ARYLCARBOXAMIDES | HCRTR2, HCRTR1, CNR1 | HDAC6 692/4885HDAC1 480/4885HDAC2 379/4885 |
| US-11236072-B2 | N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides | HCRTR2, HCRTR1, CNR1 | HDAC6 815/4885HDAC1 489/4885HDAC2 434/4885 |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | HDAC6 954/4885HDAC1 1019/4885HDAC2 1755/4885 |
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | HDAC6 954/4885HDAC1 1019/4885HDAC2 1755/4885 |
| US-20170298053-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | HCRTR2, HCRTR1, CNR1 | HDAC6 712/4885HDAC1 491/4885HDAC2 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.